{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:27:13Z","timestamp":1784759233913,"version":"3.55.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurologic.theclinics.com","mdconsult.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ncl.2014.09.011","type":"journal-article","created":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T06:16:58Z","timestamp":1416982618000},"page":"153-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Drug-induced Movement Disorders"],"prefix":"10.1016","volume":"33","author":[{"given":"Shyamal H.","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil D.","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib1","first-page":"19","article-title":"Chlorpromazine and neuroleptic treatments in psychiatry","volume":"17","author":"Delay","year":"1956","journal-title":"J\u00a0Clin Exp Psychopathol"},{"key":"10.1016\/j.ncl.2014.09.011_bib2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF00441188","article-title":"Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy","volume":"1","author":"Uhrbrand","year":"1960","journal-title":"Psychopharmacologia"},{"issue":"10","key":"10.1016\/j.ncl.2014.09.011_bib3","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archpsyc.1983.01790090075012","article-title":"Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes","volume":"40","author":"Keepers","year":"1983","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2014.09.011_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.ncl.2014.09.011_bib5","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1176\/ajp.135.11.1414","article-title":"Laryngeal-pharyngeal dystonia as a possible cause of asphyxia with haloperidol treatment","volume":"135","author":"Flaherty","year":"1978","journal-title":"Am J Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2014.09.011_bib6","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S1353-8020(13)70027-0","article-title":"Acute and subacute drug-induced movement disorders","volume":"20","author":"Burkhard","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.ncl.2014.09.011_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1600-0447.1990.tb03078.x","article-title":"Clinical characteristics of the Pisa syndrome","volume":"82","author":"Suzuki","year":"1990","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"10.1016\/j.ncl.2014.09.011_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00023210-200216030-00003","article-title":"Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management","volume":"16","author":"Suzuki","year":"2002","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mds.870080117","article-title":"Tardive and chronically recurrent oculogyric crises","volume":"8","author":"Sachdev","year":"1993","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.ncl.2014.09.011_bib10","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/mds.22532","article-title":"Recurrent acute dystonic reaction and oculogyric crisis despite withdrawal of dopamine receptor blocking drugs","volume":"24","author":"Schneider","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2014.09.011_bib11","series-title":"Drug-induced movement disorders","first-page":"111","article-title":"Acute and tardive dystonia","author":"Bhatt","year":"2004"},{"issue":"3","key":"10.1016\/j.ncl.2014.09.011_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4088\/JCP.v59n0307","article-title":"Cocaine as a risk factor for neuroleptic-induced acute dystonia","volume":"59","author":"van Harten","year":"1998","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2014.09.011_bib13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/archinte.162.3.358","article-title":"Acute dystonia due to metoclopramide: increased risk in AIDS","volume":"162","author":"van Der Kleij","year":"2002","journal-title":"Arch Intern Med"},{"issue":"1\u20132","key":"10.1016\/j.ncl.2014.09.011_bib14","first-page":"20","article-title":"Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys","volume":"82","author":"Neale","year":"1984","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S003329170003960X","article-title":"The pathophysiology of extrapyramidal side-effects of neuroleptic drugs","volume":"10","author":"Marsden","year":"1980","journal-title":"Psychol Med"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0091-3057(90)90141-4","article-title":"Drug specificity of pharmacological dystonia","volume":"36","author":"Matsumoto","year":"1990","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.ncl.2014.09.011_bib17","first-page":"139","article-title":"Clinical management of acute neuroleptic-induced extrapyramidal syndromes","volume":"23","author":"Keepers","year":"1986","journal-title":"Curr Psychiatr Ther"},{"key":"10.1016\/j.ncl.2014.09.011_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJM196002182620708","article-title":"Severe extrapyramidal motor activity induced by prochlorperazine. Its relief by the intravenous injection of diphenhydramine","volume":"262","author":"Waugh","year":"1960","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ncl.2014.09.011_bib19","first-page":"527","article-title":"Acute dystonic reactions that fail to respond to diphenhydramine: think of PCP","volume":"17","author":"Piecuch","year":"1999","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.ncl.2014.09.011_bib20","first-page":"704","article-title":"Akathisie","volume":"17","author":"Haskovec","year":"1902","journal-title":"Arch Bohemes Med Clin"},{"issue":"2","key":"10.1016\/j.ncl.2014.09.011_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/(SICI)1099-1077(199803)13:2<113::AID-HUP958>3.0.CO;2-N","article-title":"Immediate effects of droperidol","volume":"13","author":"Healy","year":"1998","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.ncl.2014.09.011_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1192\/bjp.143.2.139","article-title":"Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions","volume":"143","author":"Braude","year":"1983","journal-title":"Br J Psychiatry"},{"issue":"12","key":"10.1016\/j.ncl.2014.09.011_bib23","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archpsyc.1994.03950120035007","article-title":"Clinical characteristics and predisposing factors in acute drug-induced akathisia","volume":"51","author":"Sachdev","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.ncl.2014.09.011_bib24","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.1961.03040120016004","article-title":"A\u00a0survey of drug-induced extrapyramidal reactions","volume":"175","author":"Ayd","year":"1961","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ncl.2014.09.011_bib25","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archpsyc.1985.01790320042006","article-title":"Akathisia variants and tardive dyskinesia","volume":"42","author":"Barnes","year":"1985","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.ncl.2014.09.011_bib27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF02244811","article-title":"Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol","volume":"106","author":"Nordstrom","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib29","article-title":"Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia","author":"Lima","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib30","article-title":"Anticholinergics for neuroleptic-induced acute akathisia","author":"Lima","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ncl.2014.09.011_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1192\/bjp.bp.109.070540","article-title":"Acute antipsychotic-induced akathisia revisited","volume":"196","author":"Poyurovsky","year":"2010","journal-title":"Br J Psychiatry"},{"issue":"5","key":"10.1016\/j.ncl.2014.09.011_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/WNF.0b013e3181ee7f63","article-title":"Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study","volume":"33","author":"Stryjer","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"10.1016\/j.ncl.2014.09.011_bib33","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/00007611-198912000-00033","article-title":"Metoclopramide-induced parkinsonism","volume":"82","author":"Sethi","year":"1989","journal-title":"South Med J"},{"issue":"8411","key":"10.1016\/j.ncl.2014.09.011_bib34","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0140-6736(84)91516-2","article-title":"Drug-induced parkinsonism in the elderly","volume":"2","author":"Stephen","year":"1984","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib35","first-page":"10","article-title":"Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs","volume":"11","author":"Marti Masso","year":"1996","journal-title":"Neurologia"},{"issue":"6519","key":"10.1016\/j.ncl.2014.09.011_bib36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/bmj.292.6519.534","article-title":"Parkinson's disease in a Scottish city","volume":"292","author":"Mutch","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ncl.2010.10.002","article-title":"Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial","volume":"29","author":"Caroff","year":"2011","journal-title":"Neurol Clin"},{"issue":"6","key":"10.1016\/j.ncl.2014.09.011_bib38","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.51.6.850","article-title":"Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa","volume":"51","author":"Hardie","year":"1988","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1176\/jnp.2.1.64","article-title":"Asymmetry in clinical features of drug-induced parkinsonism","volume":"2","author":"Sethi","year":"1990","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"issue":"3","key":"10.1016\/j.ncl.2014.09.011_bib40","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/mds.870120307","article-title":"Freezing phenomenon in patients with parkinsonian syndromes","volume":"12","author":"Giladi","year":"1997","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ncl.2014.09.011_bib41","first-page":"169","article-title":"Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease","volume":"4","author":"Morley","year":"2013","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"8","key":"10.1016\/j.ncl.2014.09.011_bib42","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.parkreldis.2014.05.011","article-title":"Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations","volume":"20","author":"Brigo","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2014.09.011_bib43","series-title":"Psychiatric aspects of neurologic disease","first-page":"219","article-title":"Spontaneous and drug-induced movement disorders","author":"Marsden","year":"1975"},{"issue":"6","key":"10.1016\/j.ncl.2014.09.011_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000102857","article-title":"Prolonged drug-induced parkinsonism","volume":"35","author":"Klawans","year":"1973","journal-title":"Confin Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","article-title":"Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs","volume":"45","author":"Farde","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib46","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.ncl.2014.09.011_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"Spec No","key":"10.1016\/j.ncl.2014.09.011_bib48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0378-4274(92)90180-R","article-title":"Genetically determined differences in drug metabolism as a risk factor in drug toxicity","volume":"64-65","author":"Eichelbaum","year":"1992","journal-title":"Toxicol Lett"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib49","first-page":"261","article-title":"Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility","volume":"13","author":"Negrotti","year":"1992","journal-title":"Neurotoxicology"},{"issue":"6","key":"10.1016\/j.ncl.2014.09.011_bib50","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1532-5415.1969.tb01316.x","article-title":"Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism","volume":"17","author":"Forno","year":"1969","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.ncl.2014.09.011_bib51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archneur.1983.04050050093019","article-title":"Drug-induced parkinsonism and idiopathic Parkinson's disease","volume":"40","author":"Goetz","year":"1983","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2014.09.011_bib52","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/archneur.1982.00510220042009","article-title":"Reversible drug-induced parkinsonism. Clinicopathologic study of two cases","volume":"39","author":"Rajput","year":"1982","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jnnp.2008.157370","article-title":"The role of DAT-SPECT in movement disorders","volume":"81","author":"Kagi","year":"2010","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.ncl.2014.09.011_bib54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","article-title":"Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs","volume":"100","author":"Tarsy","year":"2011","journal-title":"Handb Clin Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2014.09.011_bib55","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1176\/ajp.133.8.940","article-title":"Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism","volume":"133","author":"Fann","year":"1976","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2014.09.011_bib56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000136523","article-title":"A\u00a0double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism","volume":"12","author":"Kelly","year":"1974","journal-title":"Pharmacology"},{"key":"10.1016\/j.ncl.2014.09.011_bib57","first-page":"259","article-title":"Carbidopa\/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia","volume":"37","author":"Shoulson","year":"1983","journal-title":"Adv Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2014.09.011_bib58","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1176\/ajp.137.10.1163","article-title":"Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs","volume":"137","year":"1980","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2014.09.011_bib59","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1176\/ajp.156.2.309","article-title":"Incidence of tardive dyskinesia in early\u00a0stages of low-dose treatment with typical neuroleptics in older patients","volume":"156","author":"Jeste","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: prevalence and risk factors, 1959 to 1979","volume":"39","author":"Kane","year":"1982","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2014.09.011_bib61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib62","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/schbul\/18.4.701","article-title":"Gender differences in tardive dyskinesia: a critical review of the literature","volume":"18","author":"Yassa","year":"1992","journal-title":"Schizophr Bull"},{"issue":"6","key":"10.1016\/j.ncl.2014.09.011_bib63","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1176\/ajp.150.6.966","article-title":"Diabetes and development of tardive dyskinesia","volume":"150","author":"Woerner","year":"1993","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.ncl.2014.09.011_bib64","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1176\/ajp.135.11.1321","article-title":"Withdrawal syndromes associated with antipsychotic drugs","volume":"135","author":"Gardos","year":"1978","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.ncl.2014.09.011_bib65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/YIC.0b013e32834aa924","article-title":"Tardive Tourette-like syndrome: a systematic review","volume":"26","author":"Fountoulakis","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.ncl.2014.09.011_bib66","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1176\/ajp.137.10.1267","article-title":"Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration","volume":"137","author":"Stahl","year":"1980","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mds.870020408","article-title":"Tardive myoclonus","volume":"2","author":"Little","year":"1987","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mds.870070110","article-title":"Tardive tremor","volume":"7","author":"Stacy","year":"1992","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2014.09.011_bib69","first-page":"167","article-title":"Drug induced dystonia tarda: treatment with L-dopa","volume":"34","author":"Keegan","year":"1973","journal-title":"Dis Nerv Syst"},{"issue":"12","key":"10.1016\/j.ncl.2014.09.011_bib70","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/WNL.32.12.1335","article-title":"Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs","volume":"32","author":"Burke","year":"1982","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib71","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mds.870050411","article-title":"Prevalence of dystonia in veterans on chronic antipsychotic therapy","volume":"5","author":"Sethi","year":"1990","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.ncl.2014.09.011_bib72","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1600-0447.1986.tb02735.x","article-title":"Prevalence of tardive dystonia","volume":"73","author":"Yassa","year":"1986","journal-title":"Acta Psychiatr Scand"},{"issue":"2\u20133","key":"10.1016\/j.ncl.2014.09.011_bib73","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0920-9964(95)00096-8","article-title":"The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I","volume":"19","author":"van Harten","year":"1996","journal-title":"Schizophr Res"},{"issue":"6","key":"10.1016\/j.ncl.2014.09.011_bib74","doi-asserted-by":"crossref","first-page":"646.e9","DOI":"10.1016\/j.genhosppsych.2010.04.009","article-title":"Duloxetine-related tardive dystonia and tardive dyskinesia: a case report","volume":"32","author":"Chen","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib75","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00702-013-1108-8","article-title":"Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine","volume":"121","author":"Dressler","year":"2014","journal-title":"J\u00a0Neural Transm"},{"issue":"5","key":"10.1016\/j.ncl.2014.09.011_bib76","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.parkreldis.2014.02.005","article-title":"Drug induced oromandibular dystonia: A case related to prolonged use of cetirizine","volume":"20","author":"Pellecchia","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.ncl.2014.09.011_bib77","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.870010305","article-title":"Natural history and treatment of tardive dystonia","volume":"1","author":"Kang","year":"1986","journal-title":"Mov Disord"},{"issue":"Pt 11","key":"10.1016\/j.ncl.2014.09.011_bib78","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/brain\/121.11.2053","article-title":"The natural history of tardive dystonia. A long-term follow-up study of 107 cases","volume":"121","author":"Kiriakakis","year":"1998","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.ncl.2014.09.011_bib79","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/ajp.148.8.1055","article-title":"A\u00a0review of 32 cases of tardive dystonia","volume":"148","author":"Wojcik","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib80","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/mds.870040107","article-title":"Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia","volume":"4","author":"Andersson","year":"1989","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.ncl.2014.09.011_bib81","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1212\/WNL.48.6.1571","article-title":"Secondary dystonia and the DYTI gene","volume":"48","author":"Bressman","year":"1997","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2014.09.011_bib82","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1600-0447.1985.tb05061.x","article-title":"Tardive dystonia and severe tardive dyskinesia. A comparison of risk factors and prognosis","volume":"71","author":"Gimenez-Roldan","year":"1985","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"10.1016\/j.ncl.2014.09.011_bib83","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mds.870040208","article-title":"Tardive akathisia: an analysis of clinical features and response to open therapeutic trials","volume":"4","author":"Burke","year":"1989","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.ncl.2014.09.011_bib84","first-page":"1494","article-title":"Course of psychopathologic and extrapyramidal motor symptoms during long-term treatment of schizophrenic patients with psycholeptic drugs (author's transl)","volume":"28","author":"Schilkrut","year":"1978","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"10.1016\/j.ncl.2014.09.011_bib85","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/mds.870090211","article-title":"Withdrawal akathisia: case reports and a proposed classification of chronic akathisia","volume":"9","author":"Lang","year":"1994","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib86","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF02245462","article-title":"Research diagnostic criteria for drug-induced akathisia: conceptualization, rationale and proposal","volume":"114","author":"Sachdev","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2014.09.011_bib87","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/S1353-8020(13)70028-2","article-title":"Tardive dyskinesia syndromes: current concepts","volume":"20","author":"Aquino","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"10.1016\/j.ncl.2014.09.011_bib88","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.25107","article-title":"Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis","volume":"27","author":"Teo","year":"2012","journal-title":"Mov Disord"},{"issue":"5966","key":"10.1016\/j.ncl.2014.09.011_bib89","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/309347a0","article-title":"Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis","volume":"309","author":"Gunne","year":"1984","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ncl.2014.09.011_bib90","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/YCO.0b013e3283568537","article-title":"Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics","volume":"25","author":"Ferentinos","year":"2012","journal-title":"Curr Opin Psychiatry"},{"issue":"8","key":"10.1016\/j.ncl.2014.09.011_bib91","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2012.04.032","article-title":"Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba","volume":"72","author":"Zhang","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ncl.2014.09.011_bib92","series-title":"Drug-induced movement disorders","first-page":"77","article-title":"Clinical features and management of classic tardive dyskinesia, tardive myoclonus, tardive tremor and tardive tourettism","author":"De Leon","year":"2004"},{"issue":"2","key":"10.1016\/j.ncl.2014.09.011_bib93","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.09.011_bib94","first-page":"267","article-title":"Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents","volume":"37","author":"Fahn","year":"1983","journal-title":"Adv Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2014.09.011_bib95","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/jnnp.37.8.941","article-title":"Effect of cholinergic and anticholinergic agents on tardive dyskinesia","volume":"37","author":"Klawans","year":"1974","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.ncl.2014.09.011_bib96","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","volume":"3","author":"Waln","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"5","key":"10.1016\/j.ncl.2014.09.011_bib97","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2014.09.011_bib98","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4088\/JCP.09m05125yel","article-title":"Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Zhang","year":"2011","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2014.09.011_bib99","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.parkreldis.2012.09.016","article-title":"Globus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literature","volume":"19","author":"Spindler","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.ncl.2014.09.011_bib100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00002826-199702000-00012","article-title":"An open-label study of botulinum toxin A for treatment of tardive dystonia","volume":"20","author":"Tarsy","year":"1997","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"10.1016\/j.ncl.2014.09.011_bib101","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/0269881109103827","article-title":"Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature","volume":"24","author":"Peritogiannis","year":"2010","journal-title":"J\u00a0Psychopharmacol"},{"issue":"3","key":"10.1016\/j.ncl.2014.09.011_bib102","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archpsyc.55.3.279","article-title":"Marked reduction of tardive dyskinesia with olanzapine","volume":"55","author":"Littrell","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib103","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mds.870120403","article-title":"The emerging role of clozapine in the treatment of movement disorders","volume":"12","author":"Factor","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2014.09.011_bib104","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.158.4.503","article-title":"The effects of clozapine on tardive dyskinesia","volume":"158","author":"Lieberman","year":"1991","journal-title":"Br J Psychiatry"},{"issue":"6","key":"10.1016\/j.ncl.2014.09.011_bib105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ajp.2013.08.067","article-title":"Clozapine and tardive movement disorders: a review","volume":"6","author":"Hazari","year":"2013","journal-title":"Asian J Psychiatr"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib106","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4306\/pi.2013.10.4.417","article-title":"Beneficial effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases","volume":"10","author":"Albayrak","year":"2013","journal-title":"Psychiatry Investig"},{"issue":"7","key":"10.1016\/j.ncl.2014.09.011_bib107","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1176\/ajp.137.7.776","article-title":"Overview: public health issues in tardive dyskinesia","volume":"137","author":"Gardos","year":"1980","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ncl.2014.09.011_bib108","first-page":"49","article-title":"Toxin and drug-induced myoclonus","volume":"89","author":"Gordon","year":"2002","journal-title":"Adv Neurol"},{"key":"10.1016\/j.ncl.2014.09.011_bib109","series-title":"Myoclonus","first-page":"251","article-title":"Drug-induced myoclonus","author":"Klawans","year":"1986"},{"key":"10.1016\/j.ncl.2014.09.011_bib110","series-title":"Drug-induced movement disorders","first-page":"339","article-title":"Miscellaneous drug-induced movement disorders","author":"Lang","year":"1992"},{"issue":"4","key":"10.1016\/j.ncl.2014.09.011_bib111","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","article-title":"Treatment of ADHD in children with tics: a randomized controlled trial","volume":"58","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.09.011_bib112","series-title":"Drug-induced movement disorders","first-page":"233","article-title":"Movement disorders induced by selective serotonin reuptake inhibitors and other antidepressants","author":"Bharucha","year":"2004"},{"key":"10.1016\/j.ncl.2014.09.011_bib113","series-title":"Drug-induced movement disorders","first-page":"309","article-title":"Antiepileptic drug-induced movement disorders","author":"Kellett","year":"2004"},{"key":"10.1016\/j.ncl.2014.09.011_bib114","series-title":"Drug-induced movement disorders","first-page":"295","article-title":"Stimulant-induced movement disorders","author":"Sanchez-Ramos","year":"2004"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861914000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861914000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:07:33Z","timestamp":1747170453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861914000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0733861914000796"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2014.09.011","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced Movement Disorders","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2014.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}